La Vecchia C, Malvezzi M, Bosetti C, Garavello W, Bertuccio P, Levi F et al. Thyroid cancer mortality and incidence: a global overview. Int J Cancer 2015; 136: 2187–2195.
Lim H, Devesa SS, Sosa JA, Check D, Kitahara CM. Trends in thyroid cancer incidence and mortality in the United States, 1974-2013. JAMA 2017; 317: 1338–1348.
Surveillance, Epidemiology, and End Results (SEER) Program (Research Data (1973–2014), National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2017, based on the November 2016 submission). Available at: http://www.seer.cancer.gov.
Nixon IJ, Ganly I, Patel SG, Palmer FL, Di Lorenzo MM, Grewal RK et al. The results of selective use of radioactive iodine on survival and on recurrence in the management of papillary thyroid cancer, based on Memorial Sloan-Kettering Cancer Center risk group stratification. Thyroid 2013; 23: 683–694.
Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE et al. American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid 2016 2015; 26: 1–133.
Mallick U, Harmer C, Yap B, Wadsley J, Clarke S, Moss L et al. Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. N Engl J Med 2012; 366: 1674–1685.
Schlumberger M, Catargi B, Borget I, Deandreis D, Zerdoud S, Bridji B et al. Strategies of radioiodine ablation in patients with low-risk thyroid cancer. N Engl J Med 2012; 366: 1663–1673.
American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid CancerCooper DS American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid CancerDoherty GM American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid CancerHaugen BR American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid CancerKloos RT American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid CancerLee SL et alAmerican Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19: 1167–1214.
Iyer NG, Morris LG, Tuttle RM, Shaha AR, Ganly I. Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy. Cancer 2011; 117: 4439–4446.
Teng CJ, Hu YW, Chen SC, Yeh CM, Chiang HL, Chen TJ et al. Use of radioactive iodine for thyroid cancer and risk of second primary malignancy: a nationwide population-based study. J Natl Cancer Inst 2016; 108: 2.
Sawka AM, Thabane L, Parlea L, Ibrahim-Zada I, Tsang RW, Brierley JD et al. Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. Thyroid 2009; 19: 451–457.
Subramanian S, Goldstein DP, Parlea L, Thabane L, Ezzat S, Ibrahim-Zada I et al. Second primary malignancy risk in thyroid cancer survivors: a systematic review and meta-analysis. Thyroid 2007; 17: 1277–1288.
Klimek VM, Tray NJ. Therapy-related myeloid neoplasms: what's in a name? Curr Opin Hematol 2016; 23: 161–166.
Hsu WL, Preston DL, Soda M, Sugiyama H, Funamoto S, Kodama K et al. The incidence of leukemia, lymphoma and multiple myeloma among atomic bomb survivors: 1950-2001. Radiat Res 2013; 179: 361–382.
Iwanaga M, Hsu WL, Soda M, Takasaki Y, Tawara M, Joh T et al. Risk of myelodysplastic syndromes in people exposed to ionizing radiation: a retrospective cohort study of Nagasaki atomic bomb survivors. J Clin Oncol 2011; 29: 428–434.
Radivoyevitch T, Sachs RK, Gale RP, Molenaar RJ, Brenner DJ, Hill BT et al. Defining AML and MDS second cancer risk dynamics after diagnoses of first cancers treated or not with radiation. Leukemia 2016; 30: 285–294.
Lassmann M, Reiners C, Luster M. Dosimetry and thyroid cancer: the individual dosage of radioiodine. Endocr Relat Cancer 2010; 17: R161–R172.
Altman DG, Bland JM. How to obtain the confidence interval from a P value. BMJ 2011; 343: d2090.
R Core Team. R: A Language And Environment For Statistical Computing. R Foundation for Statistical Computing: Vienna, Austria, 2017..
Nardi V, Winkfield KM, Ok CY, Niemierko A, Kluk MJ, Attar EC et al. Acute myeloid leukemia and myelodysplastic syndromes after radiation therapy are similar to de novo disease and differ from other therapy-related myeloid neoplasms. J Clin Oncol 2012; 30: 2340–2347.
Barrington SF, Kettle AG, O'Doherty MJ, Wells CP, Somer EJ, Coakley AJ. Radiation dose rates from patients receiving iodine-131 therapy for carcinoma of the thyroid. Eur J Nucl Med 1996; 23: 123–130.
Ravichandran R, Binukumar J, Saadi AA. Estimation of effective half life of clearance of radioactive Iodine (I) in patients treated for hyperthyroidism and carcinoma thyroid. Indian J Nucl Med 2010; 25: 49–52.
Monteiro Gil O, Oliveira NG, Rodrigues AS, Laires A, Ferreira TC, Limbert E et al. Cytogenetic alterations and oxidative stress in thyroid cancer patients after iodine-131 therapy. Mutagenesis 2000; 15: 69–75.
Erselcan T, Sungu S, Ozdemir S, Turgut B, Dogan D, Ozdemir O. Iodine-131 treatment and chromosomal damage: in vivo dose-effect relationship. Eur J Nucl Med Mol Imaging 2004; 31: 676–684.
de Moor JS, Mariotto AB, Parry C, Alfano CM, Padgett L, Kent EE et al. Cancer survivors in the United States: prevalence across the survivorship trajectory and implications for care. Cancer Epidemiol Biomarkers Prev 2013; 22: 561–570.
Rollison DE, Howlader N, Smith MT, Strom SS, Merritt WD, Ries LA et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 2008; 112: 45–52.
Gillis NK, Ball M, Zhang Q, Ma Z, Zhao Y, Yoder SJ et al. Clonal haemopoiesis and therapy-related myeloid malignancies in elderly patients: a proof-of-concept, case-control study. Lancet Oncol 2017; 18: 112–121.
Takahashi K, Wang F, Kantarjian H, Doss D, Khanna K, Thompson E et al. Preleukaemic clonal haemopoiesis and risk of therapy-related myeloid neoplasms: a case-control study. Lancet Oncol 2017; 18: 100–111.
Wong TN, Ramsingh G, Young AL, Miller CA, Touma W, Welch JS et al. Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia. Nature 2015; 518: 552–555.
Keegan THM, Bleyer A, Rosenberg AS, Li Q, Goldfarb M. Second primary malignant neoplasms and survival in adolescent and young adult cancer survivors. JAMA Oncol 2017; 3: 1554–1557.
Sidana S, Elson P, Gerds AT, Carraway HE, Advani AS, Saunthararajah Y et al. Survival outcomes of leukemias and myelodysplastic syndromes occurring as second cancers in the United States: A SEER registry-based population analysis. Blood 2015; 126: 2507.
Jagsi R, Abrahamse P, Hawley ST, Graff JJ, Hamilton AS, Katz SJ. Underascertainment of radiotherapy receipt in Surveillance, Epidemiology, and End Results registry data. Cancer 2012; 118: 333–341.
Veiga LH, Lubin JH, Anderson H, de Vathaire F, Tucker M, Bhatti P et al. A pooled analysis of thyroid cancer incidence following radiotherapy for childhood cancer. Radiat Res 2012; 178: 365–376.
Schneider AB, Sarne DH. Long-term risks for thyroid cancer and other neoplasms after exposure to radiation. Nat Clin Pract Endocrinol Metab 2005; 1: 82–91.
Ron E, Lubin JH, Shore RE, Mabuchi K, Modan B, Pottern LM et al. Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. Radiat Res 1995; 141: 259–277.
Pearce MS, Salotti JA, Little MP, McHugh K, Lee C, Kim KP et al. Radiation exposure from CT scans in childhood and subsequent risk of leukaemia and brain tumours: a retrospective cohort study. Lancet 2012; 380: 499–505.